Insider Selling: Keros Therapeutics (NASDAQ:KROS) Director Sells $28,166.25 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Nima Farzan sold 2,625 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director directly owned 9,767 shares of the company’s stock, valued at $104,799.91. The trade was a 21.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $9.93 on Thursday. The firm has a market cap of $196.51 million, a P/E ratio of -3.30 and a beta of 0.94. Keros Therapeutics, Inc. has a 1-year low of $9.79 and a 1-year high of $22.55. The firm has a fifty day moving average of $11.28 and a two-hundred day moving average of $15.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. On average, sell-side analysts expect that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

Institutional Trading of Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. Financial Management Professionals Inc. acquired a new stake in Keros Therapeutics in the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd increased its position in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the period. Tower Research Capital LLC TRC increased its position in Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the period. Lazard Asset Management LLC acquired a new stake in Keros Therapeutics in the 1st quarter valued at approximately $129,000. Finally, New York State Common Retirement Fund raised its position in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on KROS shares. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Hold” and an average price target of $20.40.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.